Eli Lilly secures FDA approval for Foundayo, first non-peptide weight loss pill
Eli Lilly and Company (NYSE:LLY) announced on Wednesday, April 1, 2026, that the U.S. Food and Drug Administration (FDA) has approved Foundayo™ (orforglipron) for chronic weight management in adults with obesity, or those who are overweight with at least one weight-related condition.











